Olaparib (Lynparza) and the PARP Inhibitor Landscape

Olaparib, sold as Lynparza, was the first PARP inhibitor approved for cancer treatment. It put the concept of synthetic lethality into clinical practice: tumors with defects in homologous recombination repair, such as those with BRCA1 or BRCA2 mutations, become especially dependent on PARP and are vulnerable when it is blocked.

Mechanism at a glance

Olaparib inhibits PARP enzymes, including PARP1, PARP2 and PARP3, that are involved in repairing single-strand DNA breaks. In cells that also cannot repair double-strand breaks through homologous recombination, the accumulated damage is lethal. It is taken orally twice daily; anemia, nausea and fatigue are common. Myelodysplastic syndrome and acute myeloid leukemia are a labeled warning: in the US label’s pooled data about 1.2% of patients (26 of 2,219) developed MDS/AML, and 54% of those cases were fatal.

Where it is used

• Ovarian cancer: first-line maintenance in BRCA-mutated disease after platinum response, in combination with bevacizumab for HRD-positive tumors, and maintenance in recurrent BRCA-mutated disease (current US label).
• Breast cancer: in germline BRCA-mutated HER2-negative disease, including the adjuvant setting for high-risk patients.
• Pancreatic and prostate cancers: maintenance in germline BRCA-mutated metastatic pancreatic cancer; in prostate cancer, homologous recombination repair-mutated metastatic castration-resistant disease as monotherapy and, with abiraterone, BRCA-mutated disease.

The competitive set

Niraparib and talazoparib remain important competitors in selected settings, and each has a different profile in safety, dosing and biomarker strategy. Rucaparib’s role has narrowed: per FDA authors, its treatment indication in BRCA-mutated or HRD-positive advanced ovarian cancer was withdrawn and its recurrent-ovarian maintenance indication was limited to BRCA-mutated disease, and its current US label lists BRCA-mutated recurrent ovarian maintenance and BRCA-mutated metastatic castration-resistant prostate cancer after androgen receptor-directed therapy. A new wave of PARP1-selective inhibitors aims to preserve efficacy while reducing hematologic toxicity associated with inhibiting PARP2. AstraZeneca’s saruparib (AZD5305) is in Phase 3 (EvoPAR), but I found no reported Phase 3 efficacy data.

Regulatory scrutiny in ovarian cancer

The class has faced scrutiny around overall survival in some ovarian cancer populations. FDA authors reported in the Journal of Clinical Oncology (2025) that six PARP-inhibitor ovarian indications approved from 2014 to 2019 were withdrawn or narrowed in 2022 and 2023 after a potential detrimental effect on overall survival was seen in four randomized trials. For niraparib, olaparib and rucaparib, the treatment indications in BRCA-mutated or HRD-positive advanced ovarian cancer were withdrawn, and the recurrent-disease maintenance indications were narrowed to BRCA-mutated patients. GSK links part of the recent fall in Zejula (niraparib) sales to the FDA label update and prior-authorization requirements.

Questions to keep asking

1. How are label restrictions and biomarker requirements changing in practice?
2. What is the place of PARP inhibitors alongside hormone therapies in prostate cancer?
3. How significant are resistance mechanisms, such as BRCA reversion mutations?
4. Will PARP1-selective drugs shift the class’s tolerability expectations?

Biomarker testing rates may be as important as drug performance in determining real-world adoption, and our guide to oncology competitive intelligence explains how to monitor both.

Recent developments

Updated October 8, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Jul 2026: AstraZeneca reported Lynparza revenue of $1,610 million for the first half of 2026 (up 3%, down 1% at constant exchange rates) and $829 million for Q2 (down 1%, or 3% at constant rates). Full-year 2025 revenue was $3,279 million. (AstraZeneca 6-K)
• Jul 2026: GSK reported Zejula (niraparib) sales of £101 million in Q2 2026 (down 33%) and £215 million for the first half (down 24%). GSK attributes the US decline to the FDA label update and new prior-authorization requirements, and the European decline to increased competition. (GSK filing)
• Feb 2026: AstraZeneca disclosed that it will not file Lynparza plus Imfinzi and bevacizumab (DUO-O) for first-line ovarian cancer in the US, Europe, China or Japan, citing further data follow-up and health authority interactions. (AstraZeneca 6-K)
• Dec 12, 2025: FDA approved Akeega (niraparib plus abiraterone) with prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer (AMPLITUDE). (FDA)
• Jul 2025: FDA authors published a review in the Journal of Clinical Oncology of the PARP-inhibitor ovarian cancer indications withdrawn or narrowed after overall survival concerns. (PubMed)
• Dec 2024: OlympiA long-term follow-up in germline BRCA-mutated, HER2-negative high-risk early breast cancer: overall survival HR 0.72, six-year OS 87.5% vs 83.2% (company-reported). (Merck)

Upcoming catalysts

• Sept 30, 2027 (estimated): primary completion of EvoPAR-Prostate01, the saruparib Phase 3 in metastatic castration-sensitive prostate cancer (1,898 patients), per ClinicalTrials.gov. A primary completion date is not a readout date, and the company has not guided on timing.
• Dec 2029 (estimated): primary completion of EvoPAR-Breast01.
• US generics: I found no disclosed generic launch date. Merck’s 10-Q amortizes Lynparza intangible assets “through 2028,” which is an accounting estimate and not a stated generic date.

Bottom line

Olaparib’s legacy is as much about biomarkers as the drug itself. Adoption depends on how widely patients are tested, which makes diagnostic uptake a competitive variable alongside efficacy, and ovarian cancer shows how label narrowing can reshape a whole class.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.